Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332806 | 0.89 | — | — | |
| SCHEMBL11172685 | 0.89 | — | — | |
| SCHEMBL8734400 | 0.89 | — | — | |
| SCHEMBL29510754 | 0.89 | — | — | |
| SCHEMBL1331563 | 0.89 | — | — | |
| SCHEMBL35516 | 0.89 | — | — | |
| SCHEMBL4838188 | 0.85 | — | — | |
| SCHEMBL21243861 | 0.85 | — | — | |
| SCHEMBL8182877 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL7390873 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108355498-B | Negative charge composite nanofiltration membrane and preparation method thereof | 广州中国科学院先进技术研究所 | 2020-06-30 | — | — | CN | disclosed |
| EP-3013845-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2020-03-18 | — | — | EP | disclosed |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2019-08-13 | — | — | US | disclosed |
| US-20170114090-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS HINIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-04-27 | — | — | US | disclosed |
| EP-3013845-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | Forendo Pharma Ltd (FI) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207309-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | HSD17B1, HSD17B11, HSD17B3 | FFAR3 1262/4885TSHR 1288/4885ALDH1A1 46/4885 |
| US-20170114090-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS HINIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | HSD17B1, HSD17B11, HSD17B3 | FFAR3 1303/4885TSHR 2281/4885ALDH1A1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.